Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 5/2013

Open Access 01-10-2013 | Nephrology - Editorial

The lipid story in chronic kidney disease: a long story with a happy end?

Authors: Agata Kujawa-Szewieczek, Andrzej Więcek, Grzegorz Piecha

Published in: International Urology and Nephrology | Issue 5/2013

Login to get access

Abstract

Cardiovascular (CV) morbidity and mortality increase with the severity of kidney disease, reaching 30 times higher mortality rates in dialysis patients compared with the general population. Although dyslipidemia is a well-established CV risk factor in the general population, the relationship between lipid disorders and CV risk in patients with chronic kidney disease (CKD) is less clear. Despite the clear evidence that statins reduce the risk of atherosclerotic events and death from cardiac causes in individuals without CKD, the use of statins in patients with kidney disease is significantly less frequent. For a long time, one of the explanations was the lack of a prospective, randomized, controlled study designed specifically to CKD patients. After recent publication of the data from Study of Heart and Renal Protection trial, given the safety and potential efficacy of statins, this lipid-lowering treatment should be administered more frequently to individuals with CKD stage 1–4, as well as those undergoing dialysis.
Literature
1.
Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154–2169PubMed
2.
Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305PubMed
3.
Shulman NB, Ford CE, Hall WD et al (1989) Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the hypertension detection and follow-up program. Hypertension 13:80–93
4.
Muntner P, Hamm LL, Kusek JW et al (2004) The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140:9–17PubMed
5.
Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278PubMed
6.
Tonelli M, Isles C, Curhan GC et al (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110:1557–1563PubMed
7.
Tonelli M, Keech A, Shepherd J et al (2005) Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 16:3748–3754PubMed
8.
Sever PS, Dahlöf B, Poulter NR et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149–1158PubMed
9.
Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22
10.
Szummer K, Lundman P, Jacobson SH et al (2011) Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. Kidney Int 79:997–1004PubMed
11.
Kendrick J, Shlipak MG, Targher G et al (2010) Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis 55:42–49PubMed
12.
Colhoun HM, Betteridge DJ, Durrington PN et al (2009) Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 54:810–819PubMed
13.
Ridker PM, MacFadyen J, Cressman M et al (2010) Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the use of statins in prevention-an intervention trial evaluating rosuvastatin) trial. J Am Coll Cardiol 55:1266–1273PubMed
14.
Holdaas H, Wanner C, Abletshauser C et al (2007) The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol 117:64–74PubMed
15.
Baigent C, Blackwell L, Emberson J et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670–1681PubMed
16.
Holdaas H, Fellström B, Cole E et al (2005) Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 5:2929–2936PubMed
17.
Holdaas H, Fellström B, Jardine AG et al (2005) Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 20:974–980PubMed
18.
Wiesbauer F, Heinze G, Mitterbauer C et al (2008) Statin use is associated with prolonged survival of renal transplant recipients. J Am Soc Nephrol 19:2211–2218PubMed
19.
Baigent C, Landray MJ, Reith C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377:2181–2192PubMed
20.
EBPG Expert Group on Renal Transplantation (2002) European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia. Nephrol Dial Transplant 17:26–28
21.
Kidney Disease Outcomes Quality Initiative (K/DOQI) Group (2003) K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41:1–91
22.
Chmielewski M, Carrero JJ, Nordfors L et al (2008) Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol 21:635–644PubMed
23.
Attman PO, Knight-Gibson C, Tavella M et al (1998) The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 13:2833–2841PubMed
24.
Hirano T, Sakaue T, Misaki A et al (2003) Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. Kidney Int 63:2171–2177PubMed
25.
Nishizawa Y, Shoji T, Kawagishi T et al (1997) Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int Suppl 62:90–92
26.
Arnadottir M, Nilsson-Ehle P (1995) Has parathyroid hormone any influence on lipid metabolism in chronic renal failure? Nephrol Dial Transplant 10:2381–2382PubMed
27.
Vaziri ND, Liang K (1997) Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int 51:913–919PubMed
28.
Kim C, Vaziri ND (2005) Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int 67:1028–1032PubMed
29.
Heeringa P, Tervaert JW (2002) Role of oxidized low-density lipoprotein in renal disease. Curr Opin Nephrol Hypertens 11:287–293PubMed
30.
Kasahara J, Kobayashi K, Maeshima Y et al (2004) Clinical significance of serum oxidized low-density lipoprotein/beta2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Pract 98:15–24
31.
Deighan CJ, Caslake MJ, McConnell M et al (2000) Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 35:852–862PubMed
32.
O’Neal D, Lee P, Murphy B et al (1996) Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 27:84–91PubMed
33.
Guarnieri GF, Moracchiello M, Campanacci L et al (1978) Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl 8:26–30
34.
McLeod R, Reeve CE, Frohlich J (1984) Plasma lipoproteins and lecithin:cholesterol acyltransferase distribution in patients on dialysis. Kidney Int 25:683–688PubMed
35.
Vaziri ND (2006) Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290:262–272
36.
Vaziri ND, Deng G, Liang K (1999) Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplantc 14:1462–1466
37.
Joven J, Villabona C, Vilella E et al (1990) Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323:579–584PubMed
38.
Vaziri ND, Sato T, Liang K (2003) Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int 63:1756–1763PubMed
39.
Vaziri ND (2003) Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 63:1964–1976PubMed
40.
Kashyap ML, Srivastava LS, Hynd BA et al (1980) Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis 35:29–40PubMed
41.
Vaziri ND, Kim CH, Phan D et al (2004) Up-regulation of hepatic Acyl CoA: diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome. Kidney Int 66:262–267PubMed
42.
Ohta T, Matsuda I (1981) Lipid and apolipoprotein levels in patients with nephrotic syndrome. Clin Chim Acta 117:133–143PubMed
43.
Alexander JH, Schapel GJ, Edwards KD (1974) Increased incidence of coronary heart disease associated with combined elevation of serum triglyceride and cholesterol concentrations in the nephrotic syndrome in man. Med J Aust 2:119–122PubMed
44.
Joven J, Rubiés-Prat J, Espinel E et al (1987) High-density lipoproteins in untreated idiopathic nephrotic syndrome without renal failure. Nephrol Dial Transplant 2:149–153PubMed
45.
Cheung AK, Wu LL, Kablitz C et al (1993) Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 22:271–276PubMed
46.
Rapoport J, Aviram M, Chaimovitz C et al (1978) Defective high-density lipoprotein composition in patients on chronic hemodialysis. A possible mechanism for accelerated atherosclerosis. N Engl J Med 299:1326–1329PubMed
47.
Attman PO, Alaupovic P (1991) Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 57:401–410PubMed
48.
Näsström B, Stegmayr B, Olivecrona G et al (2004) Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. BMC Nephrol 5:17PubMed
49.
Blankestijn PJ, Vos PF, Rabelink TJ et al (1995) High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 5:1703–1708PubMed
50.
Attman PO, Samuelsson OG, Moberly J et al (1999) Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 55:1536–1542PubMed
51.
Kronenberg F, Lingenhel A, Neyer U et al (2003) Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl 84:113–116
52.
Kronenberg F, König P, Neyer U et al (1995) Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6:110–120PubMed
53.
Johansson AC, Samuelsson O, Attman PO et al (2000) Dyslipidemia in peritoneal dialysis–relation to dialytic variables. Perit Dial Int 20:306–314PubMed
54.
Prinsen BH, Rabelink TJ, Romijn JA et al (2004) A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. Kidney Int 65:1064–1075PubMed
55.
Steele J, Billington T, Janus E et al (1989) Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis. Atherosclerosis 79:47–50PubMed
56.
Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:112–119
57.
Sarnak MJ, Coronado BE, Greene T et al (2002) Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 5:327–335
58.
Coresh J, Longenecker JC, Miller ER III et al (1998) Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 9:24–30
59.
Kronenberg F, Kuen E, Ritz E et al (2000) Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11:105–115PubMed
60.
Kronenberg F, Neyer U, Lhotta K et al (1999) The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10:1027–1036PubMed
61.
Berlyne GM, Mallick NP (1969) Ischaemic heart-disease as a complication of nephrotic syndrome. Lancet 2:399–400PubMed
62.
Wass V, Cameron JS (1981) Cardiovascular disease and the nephrotic syndrome: the other side of the coin. Nephron 27:58–61PubMed
63.
Ordoñez JD, Hiatt RA, Killebrew EJ et al (1993) The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638–642PubMed
64.
Lechner BL, Bockenhauer D, Iragorri S et al (2004) The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. Pediatr Nephrol 19:744–748PubMed
65.
Cheung AK, Sarnak MJ, Yan G et al (2000) Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353–362PubMed
66.
Cressman MD, Heyka RJ, Paganini EP et al (1992) Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475–482PubMed
67.
Hahn R, Oette K, Mondorf H et al (1983) Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 48:279–288PubMed
68.
Iseki K, Yamazato M, Tozawa M et al (2002) Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61:1887–1893PubMed
69.
Kalantar-Zadeh K, Kopple JD, Block G et al (2001) A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 38:1251–1263PubMed
70.
Kilpatrick RD, McAllister CJ, Kovesdy CP et al (2007) Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 18:293–303PubMed
71.
Lowrie EG, Lew NL (1990) Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458–482PubMed
72.
Liu Y, Coresh J, Eustace JA et al (2004) Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291:451–459PubMed
73.
Koda Y, Nishi S, Suzuki M et al (1999) Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int Suppl 71:251–253
74.
Webb AT, Brown EA (1993) Prevalence of symptomatic arterial disease and risk factors for its development in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 13:406–408
75.
Olivares J, Cruz C, Gas JM et al (1992) Evolution of lipid profiles in long-term peritoneal dialysis. Adv Perit Dial 8:373–375PubMed
76.
Gault MH, Longerich L, Prabhakaran V et al (1991) Ischemic heart disease, serum cholesterol, and apolipoproteins in CAPD. ASAIO Trans 37:513–514
77.
Piccoli GB, Quarello F, Salomone M et al (1995) Are serum albumin and cholesterol reliable outcome markers in elderly dialysis patients? Nephrol Dial Transplant 10:72–77PubMed
78.
Sreedhara R, Avram MM, Blanco M et al (1996) Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. Am J Kidney Dis 28:937–942PubMed
79.
Iliescu EA, Marcovina SM, Morton AR et al (2002) Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality. Perit Dial Int 22:492–499PubMed
80.
Moorhead JF, Chan MK, El-Nahas M et al (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309–1311PubMed
81.
Galle J, Heermeier K, Wanner C (1999) Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int Suppl 71:62–65
82.
Bussolati B, Deregibus MC, Fonsato V et al (2005) Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 16:1936–1947PubMed
83.
Gyebi L, Soltani Z, Reisin E (2012) Lipid Nephrotoxicity: new concept for an old disease. Curr Hypertens Rep 14:177–181PubMed
84.
Attman PO, Alaupovic P, Samuelsson O (1999) Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. Kidney Int Suppl 71:14–17
85.
Asselbergs FW, Diercks GF, Hillege HL et al (2004) Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110:2809–2816PubMed
86.
Brouwers FP, Asselbergs FW, Hillege HL et al (2011) Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J 161:1171–1178PubMed
87.
Navaneethan SD, Pansini F, Perkovic V et al (2009) HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2:7784
88.
Holdaas H, Fellström B, Jardine AG et al (2003) Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361:2024–2031PubMed
89.
Tonelli M, Collins D, Robins S et al (2004) Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 66:1123–1130PubMed
90.
Cormack-Aboud FC, Brinkkoetter PT, Pippin JW et al (2009) Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol Dial Transplant 24:404–412PubMed
91.
Sakurai N, Kuroiwa T, Ikeuchi H et al (2009) Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy. Nephrol Dial Transplant 24:2378–2383PubMed
92.
Athyros VG, Mikhailidis DP, Papageorgiou AA et al (2004) The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57:728–734PubMed
93.
Shepherd J, Kastelein JJ, Bittner V et al (2007) Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2:1131–1139PubMed
94.
Tonelli M, Isles C, Craven T et al (2005) Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112:171–178PubMed
95.
Sandhu S, Wiebe N, Fried LF et al (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17:2006–2016PubMed
96.
Abe M, Maruyama N, Yoshida Y et al (2011) Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease. Endocr J 58:663–674PubMed
97.
Bianchi S, Bigazzi R, Caiazza A et al (2003) A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41:565–570PubMed
98.
Seliger SL, Weiss NS, Gillen DL et al (2002) HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297–304PubMed
99.
Mason NA, Bailie GR, Satayathum S et al (2005) HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45:119–126PubMed
100.
Lee JE, Oh KH, Choi KH et al (2011) Statin therapy is associated with improved survival in incident peritoneal dialysis patients: propensity-matched comparison. Nephrol Dial Transplant 26:4090–4094PubMed
101.
Wanner C, Krane V, März W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248PubMed
102.
Fellström BC, Jardine AG, Schmieder RE et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395–1407PubMed
103.
Holdaas H, Holme I, Schmieder RE et al (2011) Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol 22:1335–1341PubMed
104.
Zoccali C (2000) Cardiovascular risk in uraemic patients—is it fully explained by classical risk factors? Nephrol Dial Transplant 15:454–457PubMed
105.
Amann K, Tyralla K, Gross ML et al (2003) Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 60:13–21
106.
London GM, Guérin AP, Marchais SJ et al (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731–1740PubMed
107.
Kanbay M, Afsar B, Goldsmith D et al (2010) Sudden death in hemodialysis: an update. Blood Purif 30:135–145PubMed
Metadata
Title
The lipid story in chronic kidney disease: a long story with a happy end?
Authors
Agata Kujawa-Szewieczek
Andrzej Więcek
Grzegorz Piecha
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 5/2013
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-012-0296-8

Other articles of this Issue 5/2013

International Urology and Nephrology 5/2013 Go to the issue

Nephrology - Original Paper

Long-term renal outcome and complications in South Africans with proliferative lupus nephritis

Urology - Case Report

Unknown complication of preputial calculi: preputial skin fistula

Nephrology - Original Paper

Dialysis adequacy in Chinese anuric peritoneal dialysis patients

Nephrology - Case Report

Recurrence of fibrillary glomerulonephritis in a renal transplant recipient

Nephrology - Letter to the Editor

Cardiac device-related endocarditis in the patient with end-stage renal failure in the course of Fabry disease

Nephrology - Original Paper

Effects of high efficiency post-dilution on-line hemodiafiltration or conventional hemodialysis on residual renal function and left ventricular hypertrophy
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits